FDA Ranks DNA Cancer Detector as Safe Tool
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting the DNA test that checks for tiny amounts of blood cancer back into a safer, more controlled category called Class II. This means the test will have special rules to make sure it works well and is safe, helping patients get better access to this cool technology faster. Companies making these tests should get ready for these new rules, which aim to keep things safe without slowing down innovation.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Patients: Easier access to MRD DNA test
The FDA has classified the DNA-based test that measures minimal residual disease in hematological malignancies as Class II (special controls). The FDA says this classification will provide reasonable assurance of safety and effectiveness and will enhance patients' access by reducing regulatory burdens.
Manufacturers: Subject to Class II special controls
Companies that make the DNA-based minimal residual disease test must follow the Class II special controls identified in this FDA order. The rule says the special controls will be part of the codified classification and asks companies to prepare for the new regulatory requirements while noting the action reduces regulatory burdens.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in